Publicaciones en colaboración con investigadores/as de University of Chicago (4)

2021

  1. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

    npj Breast Cancer, Vol. 7, Núm. 1

2019

  1. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study

    Annals of Oncology, Vol. 30, Núm. 3, pp. 397-404

2018

  1. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer

    Journal of Clinical Oncology, Vol. 36, Núm. 9, pp. 884-890

2017

  1. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749